The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Perspective
Volume 347:1995-1996 December 19, 2002 Number 25
NextNext

Predictive Molecular Pathology

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by van de Vijver, M. J.
-PubMed Citation
The search for markers that can predict the outcome in an individual patient with cancer or the response of an individual tumor to specific therapies is a major focus of cancer research. Despite these efforts, estrogen and progesterone receptors and the HER2/neu gene are the only molecular targets that are analyzed routinely in newly diagnosed breast cancers. Thousands of studies of putative prognostic or predictive markers have failed to identify useful molecular markers in tumors, either because the selected genes were noninformative or because initially promising data could not be reproduced in other laboratories.

The search for prognostic and predictive . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.